Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients - Seite 2

• BELLE-2: PIK3CA status in circulating tumor DNA predicts efficacy of buparlisib plus fulvestrant in postmenopausal women with endocrine-resistant HR+/HER2- advanced breast cancer: First results from the randomized, Phase III BELLE-2 trial (SABCS Oral Presentation #S6-01; December 11, 3:15 PM CST)
• NeoPHOEBE: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer (SABCS Abstract #P1-14-01; December 9, 5:00pm CST)

Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2- advanced breast cancer (SABCS Abstract #P6-13-01; December 12, 7:30 AM CST)

Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2- breast cancer: Safety, preliminary efficacy and molecular analysis (SABCS Abstract #P3-14-01; December 10, 5:00 PM CST)

Data from the Make Your Dialogue Count (MYDC) survey, which sought to better understand how to improve communications among advanced breast cancer patients, caregivers and health care professionals, explore emotional effects of advanced breast cancer on caregivers:

• The experience of caregivers of women with metastatic breast cancer: Insights from the MYDC survey (SABCS Abstract #P1-11-06; December 9, 5:00 PM CST)

Other noteworthy data to be presented at SABCS on Tykerb^® (lapatinib) and Sandoz proposed biosimilar pegfilgrastim:

• NeoALTTO: Whole exome sequencing of pre-treatment biopsies to identify DNA aberrations associated with response to HER2-targeted therapies in breast cancer (SABCS Oral Poster #S5-01; December 11, 9:30 AM CST)
• NeoALTTO (BIG 1-06):  Breast  ultrasound (US) and mammography (Mx) and response to neoadjuvant LAP, TRAS and their combination in HER2+ breast cancer (SABCS Abstract #P6-01-04; December 12, 7:30 AM CST)
• ALTTO: The impact of early LAP-induced rash on DFS and OS (SABCS Abstract # PD5-07; December 10, 5:00 PM CST)
• Results from PROTECT 1; A randomized, double-blind trial comparing the efficacy and safety of a proposed biosimilar pegfilgrastim (LA-EP2006) with reference pegfilgrastim in patients with breast cancer (SABCS Abstract #P1-10-01; December 9, 5:00 PM CST)

To read more about the Novartis research approach and perspectives on current trends in the breast cancer treatment landscape, visit www.novartisoncology.com/stories.